glucuronide	levonorgestrel	16	14	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	16	14	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	16	15	false	none	Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	16	15	false	none	Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	16	16	false	none	Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	16	16	false	none	Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	12	10	false	none	Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  It is about 97.5 to 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin.  Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  		none	6373	none	D016912
glucuronide	levonorgestrel	12	10	false	none	Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  It is about 97.5 to 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin.  Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  		none	6373	none	D016912
glucuronide	levonorgestrel	12	12	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  		none	6373	none	D016912
glucuronide	levonorgestrel	12	12	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  		none	6373	none	D016912
glucuronide	levonorgestrel	12	13	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  		none	6373	none	D016912
glucuronide	levonorgestrel	12	13	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  		none	6373	none	D016912
glucuronide	levonorgestrel	12	14	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	12	14	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	14	12	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	14	12	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	14	13	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	14	13	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	14	14	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	14	14	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	14	15	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		none	6373	none	D016912
glucuronide	levonorgestrel	14	15	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		none	6373	none	D016912
glucuronide	levonorgestrel	14	16	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	levonorgestrel	14	16	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		none	6373	none	D016912
glucuronide	Levonorgestrel	16	14	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		none	none	none	none
glucuronide	Levonorgestrel	16	15	false	none	Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		none	none	none	none
glucuronide	Levonorgestrel	16	16	false	none	Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		none	none	none	none
glucuronide	Levonorgestrel	12	10	false	none	Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  It is about 97.5 to 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin.  Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  		none	none	none	none
glucuronide	Levonorgestrel	12	12	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  		none	none	none	none
glucuronide	Levonorgestrel	12	13	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  		none	none	none	none
glucuronide	Levonorgestrel	12	14	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		none	none	none	none
glucuronide	Levonorgestrel	14	12	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		none	none	none	none
glucuronide	Levonorgestrel	14	13	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		none	none	none	none
glucuronide	Levonorgestrel	14	14	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		none	none	none	none
glucuronide	Levonorgestrel	14	15	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		none	none	none	none
glucuronide	Levonorgestrel	14	16	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		none	none	none	none
levonorgestrel	Levonorgestrel	5	5	false	none	12.3 Pharmacokinetics    Absorption    No specific investigation of the absolute bioavailability of levonorgestrel tablets in humans has been conducted.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	5	5	false	none	12.3 Pharmacokinetics    Absorption    No specific investigation of the absolute bioavailability of levonorgestrel tablets in humans has been conducted.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	5	6	false	none	12.3 Pharmacokinetics    Absorption    No specific investigation of the absolute bioavailability of levonorgestrel tablets in humans has been conducted.  However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	5	6	false	none	12.3 Pharmacokinetics    Absorption    No specific investigation of the absolute bioavailability of levonorgestrel tablets in humans has been conducted.  However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	5	7	false	none	12.3 Pharmacokinetics    Absorption    No specific investigation of the absolute bioavailability of levonorgestrel tablets in humans has been conducted.  However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	5	7	false	none	12.3 Pharmacokinetics    Absorption    No specific investigation of the absolute bioavailability of levonorgestrel tablets in humans has been conducted.  However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	6	5	false	none	12.3 Pharmacokinetics    Absorption    No specific investigation of the absolute bioavailability of levonorgestrel tablets in humans has been conducted.  However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	6	5	false	none	12.3 Pharmacokinetics    Absorption    No specific investigation of the absolute bioavailability of levonorgestrel tablets in humans has been conducted.  However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	6	6	false	none	However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	6	6	false	none	However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	6	7	false	none	However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	6	7	false	none	However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	7	5	false	none	12.3 Pharmacokinetics    Absorption    No specific investigation of the absolute bioavailability of levonorgestrel tablets in humans has been conducted.  However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	7	5	false	none	12.3 Pharmacokinetics    Absorption    No specific investigation of the absolute bioavailability of levonorgestrel tablets in humans has been conducted.  However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	7	6	false	none	However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	7	6	false	none	However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.  After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	7	7	false	none	After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	7	7	false	none	After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	7	9	false	none	After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  See Table 2.  Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of levonorgestrel has not been evaluated.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	7	9	false	none	After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  See Table 2.  Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of levonorgestrel has not been evaluated.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	9	7	false	none	After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  See Table 2.  Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of levonorgestrel has not been evaluated.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	9	7	false	none	After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours.  See Table 2.  Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of levonorgestrel has not been evaluated.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	9	9	false	none	Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of levonorgestrel has not been evaluated.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	9	9	false	none	Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of levonorgestrel has not been evaluated.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	9	10	false	none	Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of levonorgestrel has not been evaluated.  Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	9	10	false	none	Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of levonorgestrel has not been evaluated.  Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	10	9	false	none	Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of levonorgestrel has not been evaluated.  Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	10	9	false	none	Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of levonorgestrel has not been evaluated.  Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	10	10	false	none	Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	10	10	false	none	Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	10	12	false	none	Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  It is about 97.5 to 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin.  Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	10	12	false	none	Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  It is about 97.5 to 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin.  Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	12	10	false	none	Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  It is about 97.5 to 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin.  Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	12	10	false	none	Distribution    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg.  It is about 97.5 to 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin.  Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	12	12	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	12	12	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	12	13	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	12	13	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	12	14	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	12	14	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	13	12	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	13	12	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	13	13	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	13	13	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	13	14	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	13	14	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	13	15	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	13	15	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	14	12	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	14	12	false	none	Metabolism    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma.  Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	14	13	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	14	13	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	14	14	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	14	14	false	none	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	14	15	true	positive	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	14	15	true	positive	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	14	16	true	positive	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	14	16	true	positive	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	15	13	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	15	13	false	none	Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel.  Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	15	14	true	positive	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	15	14	true	positive	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	15	15	true	positive	Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	15	15	true	positive	Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	15	16	false	none	Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	15	16	false	none	Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	16	14	true	positive	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	16	14	true	positive	Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates.  Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	16	15	false	none	Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	16	15	false	none	Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.  Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	16	16	false	none	Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	16	16	false	none	Excretion    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	19	19	false	none	Race: No formal studies have evaluated the effect of race on pharmacokinetics of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	19	19	false	none	Race: No formal studies have evaluated the effect of race on pharmacokinetics of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	19	20	false	none	Race: No formal studies have evaluated the effect of race on pharmacokinetics of levonorgestrel tablets.  However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets and the Yuzpe regimen (another form of emergency contraception).  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	19	20	false	none	Race: No formal studies have evaluated the effect of race on pharmacokinetics of levonorgestrel tablets.  However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets and the Yuzpe regimen (another form of emergency contraception).  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	20	19	false	none	Race: No formal studies have evaluated the effect of race on pharmacokinetics of levonorgestrel tablets.  However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets and the Yuzpe regimen (another form of emergency contraception).  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	20	19	false	none	Race: No formal studies have evaluated the effect of race on pharmacokinetics of levonorgestrel tablets.  However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets and the Yuzpe regimen (another form of emergency contraception).  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	20	20	false	none	However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets and the Yuzpe regimen (another form of emergency contraception).  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	20	20	false	none	However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets and the Yuzpe regimen (another form of emergency contraception).  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	20	22	false	none	However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets and the Yuzpe regimen (another form of emergency contraception).  The reason for this apparent increase in the pregnancy rate with emergency contraceptives in Chinese women is unknown [see USE IN SPECIFIC POPULATIONS (8.6)].  Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	20	22	false	none	However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets and the Yuzpe regimen (another form of emergency contraception).  The reason for this apparent increase in the pregnancy rate with emergency contraceptives in Chinese women is unknown [see USE IN SPECIFIC POPULATIONS (8.6)].  Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	23	23	false	none	Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	23	23	false	none	Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	23	22	false	none	Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	23	22	false	none	Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	23	24	false	none	Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  Drug-Drug Interactions    No formal drug-drug interaction studies were conducted with levonorgestrel tablets [see DRUG INTERACTIONS (7)].  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	23	24	false	none	Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  Drug-Drug Interactions    No formal drug-drug interaction studies were conducted with levonorgestrel tablets [see DRUG INTERACTIONS (7)].  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	22	20	false	none	However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets and the Yuzpe regimen (another form of emergency contraception).  The reason for this apparent increase in the pregnancy rate with emergency contraceptives in Chinese women is unknown [see USE IN SPECIFIC POPULATIONS (8.6)].  Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	22	20	false	none	However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets and the Yuzpe regimen (another form of emergency contraception).  The reason for this apparent increase in the pregnancy rate with emergency contraceptives in Chinese women is unknown [see USE IN SPECIFIC POPULATIONS (8.6)].  Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	22	23	false	none	Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	22	23	false	none	Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	22	22	false	none	Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	22	22	false	none	Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	22	24	false	none	Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  Drug-Drug Interactions    No formal drug-drug interaction studies were conducted with levonorgestrel tablets [see DRUG INTERACTIONS (7)].  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	22	24	false	none	Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  Drug-Drug Interactions    No formal drug-drug interaction studies were conducted with levonorgestrel tablets [see DRUG INTERACTIONS (7)].  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	24	23	false	none	Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  Drug-Drug Interactions    No formal drug-drug interaction studies were conducted with levonorgestrel tablets [see DRUG INTERACTIONS (7)].  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	24	23	false	none	Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  Drug-Drug Interactions    No formal drug-drug interaction studies were conducted with levonorgestrel tablets [see DRUG INTERACTIONS (7)].  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	24	22	false	none	Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  Drug-Drug Interactions    No formal drug-drug interaction studies were conducted with levonorgestrel tablets [see DRUG INTERACTIONS (7)].  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	24	22	false	none	Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.  Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.  Drug-Drug Interactions    No formal drug-drug interaction studies were conducted with levonorgestrel tablets [see DRUG INTERACTIONS (7)].  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	24	24	false	none	Drug-Drug Interactions    No formal drug-drug interaction studies were conducted with levonorgestrel tablets [see DRUG INTERACTIONS (7)].  		6373	none	D016912	none
levonorgestrel	Levonorgestrel	24	24	false	none	Drug-Drug Interactions    No formal drug-drug interaction studies were conducted with levonorgestrel tablets [see DRUG INTERACTIONS (7)].  		6373	none	D016912	none
